MD Anderson experts discuss advances in imaging AI, biomarkers, and proton therapy ahead of the 2025 ASTRO meeting.
Key Details
- 1AI tools are advancing early detection in medical imaging, including lymph node metastases previously missed by standard diagnostics.
- 2Proton therapy is becoming more widespread, with phase III trials (e.g., 440 oropharyngeal cancer patients) showing reduced toxicities versus traditional radiation.
- 3Biomarker research is personalizing prostate cancer care, such as the NRG GU006 trial using genomic tools.
- 4Theranostics and radiopharmaceuticals, like FDA-approved Pluvicto, are expanding from localized to systemic radiation treatments.
- 5MD Anderson researchers are presenting over 65 abstracts at ASTRO covering these innovations.
Why It Matters
AI's integration into medical imaging is quickly improving diagnostic accuracy and treatment personalization in oncology. These advances—especially in clinical trials and real-world applications—are set to directly impact radiology workflows and patient outcomes.
Source
EurekAlert
Related News
•EurekAlert
AI Maps Genetic Factors Shaping the Corpus Callosum via MRI Scans
USC researchers used AI to analyze MRI scans and uncover the genetic architecture of the brain's corpus callosum.
•EurekAlert
WashU Launches AI Imaging Center to Advance Precision Diagnostics
Washington University establishes a new center to develop AI-powered imaging tools for better diagnosis and precision medicine.
•EurekAlert
AI-Augmented Breath Biosensor Shows Promise for Early Lung Cancer Detection
Researchers developed an electrochemical biosensor and AI system that accurately detects lung cancer from breath samples.